Head and Neck Cancers

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Head and Neck Cancers is an early-stage landscape with 0 programs across 2 companies. The most active players are Oncolytics Biotech, Corregene Biotechnology Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

30/100

Attrition Rate

37/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Oncolytics Biotech

0 programs

Preclinical C

Corregene Biotechnology Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Terminated5 · 26%

Unknown status5 · 26%

Completed3 · 16%

Not yet recruiting2 · 11%

Withdrawn2 · 11%

Active, not recruiting1 · 5%

Other1 · 5%

Clinical Trials

Trial Activity

19 trials

Impact of Beta Hydroxy Methyl Butyrate (HMB) Supplementation on Inflammatory Markers and Clinical Outcomes in Patients With Head And Neck Cancer

Recruiting·FFederal University of Minas Gerais·Preclinical·NCT07675421·66 enrolled

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Active, not recruiting·UUniversity of Chicago·Phase 2·NCT02841748·100 enrolled

Intratumoral Gemcitabine, Paclitaxel, Carboplatine and Intravenous Nivolumab for Locally Recurrence of Head and Neck Cancers

Not yet recruiting·—·Phase 2·NCT05835804·39 enrolled

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

Not yet recruiting·UUniversity of Chicago·Phase 1/2·NCT05108870·98 enrolled

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Completed·OOncolytics Biotech·Phase 3·NCT01166542·167 enrolled

Towards a Viral Etiology of Periodontal Disease in Relation to Radiotherapy Treatment of Head and Neck Cancers

Completed·—·N/A·NCT02180932·25 enrolled

Changes in the Microenvironment of HPV-induced Head and Neck Cancers in West Indies and Metropolitan Population

Completed·UUniversity Hospital Center of Martinique·N/A·NCT03580070·140 enrolled

Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers

Terminated·AAIO-Studien-gGmbH·Phase 2·NCT03193931·47 enrolled

The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial

Terminated·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT05101798·7 enrolled

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Terminated·—·Phase 2/3·NCT01761747·3 enrolled

PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02325349·1 enrolled

Ganetespib Window of Opportunity Study in Head and Neck Cancers

Terminated·EEmory University·Phase 1·NCT02334319·3 enrolled

FACBC for Head and Neck Cancers

Withdrawn·EEmory University·Phase 1·NCT01933269

Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers

Withdrawn·—·Phase 1·NCT02442739

Hyperbaric Radiation Sensitization of Head and Neck Cancers

Unknown status·NNational Baromedical Services·Phase 2·NCT03843671·400 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)